Brief: Arcutis Completes Enrollment Of Phase 1B Alopecia Areata Study Evaluating ARQ-255
05/09/2024 13:08
Sept 5 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS COMPLETES ENROLLMENT OF PHASE 1B ALOPECIA AREATA
STUDY
EVALUATING ARQ-255
* ARCUTIS BIOTHERAPEUTICS INC: PHASE 1B RESULTS EXPECTED
FIRST
HALF OF 2025
Source text for Eikon: ID:nGNX91Vfg0
Further company coverage: ARQT.O
((Reuters.Brief@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf